Trials / Active Not Recruiting
Active Not RecruitingNCT06763835
Novel Serum Biomarkers for Identifying Plaque Erosion in ACS and Predicting Prognosis
Development and Validation of Diagnostic and Prognostic Model of Acute Coronary Syndrome Caused by Plaque Erosion Using Novel Serum Biomarkers
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 301 (actual)
- Sponsor
- Xuebo Liu · Academic / Other
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this observational study is to find novel serum biomarkers for the accurate diagnosis of plaque erosion (PE) from acute coronary syndrome (ACS) and help predicting the prognosis of PE. The main question it aims to answer is • Whether novel serum biomarkers could facilitate the non-invasive diagnosis and prognosis prediction of PE ? Participants will be contacted at 1,2,5 year after the diagnosis of PE-ACS or other reasons of ACS.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Blood is drawn to test for specific biomarkers | After identifying characteristic biomarkers that can distinguish between PE-ACS and PR-ACS, we draw blood from ACS patients for testing to assist in determining whether the ACS subtype is PE-ACS or PR-ACS. |
Timeline
- Start date
- 2023-02-01
- Primary completion
- 2024-07-30
- Completion
- 2026-07-30
- First posted
- 2025-01-08
- Last updated
- 2025-01-14
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06763835. Inclusion in this directory is not an endorsement.